PMID- 16632438
OWN - NLM
STAT- MEDLINE
DCOM- 20060524
LR  - 20220311
IS  - 1699-048X (Print)
IS  - 1699-048X (Linking)
VI  - 8
IP  - 1
DP  - 2006 Jan
TI  - Survival in extra-orbital metastatic retinoblastoma:treatment results.
PG  - 39-44
AB  - INTRODUCTION: Retinoblastoma (RB) is the most frequent malignant eye tumor in 
      childhood. In developing countries advanced stages are common. The purpose of 
      this paper is to present our 21-year clinical experience with metastatic extra 
      ocular RB patients treated with 5 different chemotherapy schemas at a single 
      Mexican Pediatric referral center. MATERIALS AND METHODS: A retrospective 
      analysis was carried out reviewing the clinical characteristics of patients with 
      metastatic RB. The information analyzed included the delay in diagnosis after 
      first symptoms, age, sex, ocular staging, and anatomic site of metastases, 
      treatment scheme, initial response and status at the last contact or date of 
      death. RESULTS: Eighty-one patients were included; age range was from 3 to 80 
      months. The most common site of metastasis was central nervous system (83.9%). 
      From those patients treated with chemotherapy (n = 74), 89.2% presented a 
      complete initial response (n = 66). Early mortality occurred in 7 cases before 
      any treatment. Fifty-six received treatment and died with progressive disease. 
      All patients without radiotherapy died with tumor activity (n = 15). The use of 
      cisplatin was related with longer disease free intervals; no other variable was 
      related with survival. Four patients were alive and disease free at 33 to 144.3 
      months of follow up from diagnosis. The prevalent cause of death was tumor 
      progression. CONCLUSIONS: In our experience, metastatic RB has a very high 
      mortality rate in spite of the use of different chemotherapy regimens.
FAU - Leal-Leal, Carlos A
AU  - Leal-Leal CA
AD  - Department of Oncology, Instituto Nacional de Pediatria, Mexico DF, Mexico. 
      drcarlosaleal@msn.com
FAU - Rivera-Luna, Roberto
AU  - Rivera-Luna R
FAU - Flores-Rojo, Martha
AU  - Flores-Rojo M
FAU - Juarez-Echenique, Juan C
AU  - Juarez-Echenique JC
FAU - Ordaz, Juan C
AU  - Ordaz JC
FAU - Amador-Zarco, Jorge
AU  - Amador-Zarco J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Italy
TA  - Clin Transl Oncol
JT  - Clinical & translational oncology : official publication of the Federation of 
      Spanish Oncology Societies and of the National Cancer Institute of Mexico
JID - 101247119
RN  - 0 (Cobalt Radioisotopes)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Bone Neoplasms/drug therapy/mortality/radiotherapy/secondary
MH  - Central Nervous System Neoplasms/drug therapy/mortality/radiotherapy/secondary
MH  - Child
MH  - Child, Preschool
MH  - Cisplatin/administration & dosage
MH  - Cobalt Radioisotopes/therapeutic use
MH  - Combined Modality Therapy
MH  - Cranial Irradiation
MH  - Disease Progression
MH  - Disease-Free Survival
MH  - Eye Neoplasms/drug therapy/*mortality/pathology/radiotherapy/surgery
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Infant
MH  - Life Tables
MH  - Liver Neoplasms/drug therapy/mortality/secondary
MH  - Male
MH  - Mexico/epidemiology
MH  - Neoadjuvant Therapy
MH  - Proportional Hazards Models
MH  - Remission Induction
MH  - Retinoblastoma/drug therapy/mortality/pathology/radiotherapy/*secondary/surgery
MH  - Retrospective Studies
MH  - Skull Neoplasms/drug therapy/mortality/radiotherapy/secondary
MH  - Survival Analysis
MH  - Treatment Outcome
RF  - 24
EDAT- 2006/04/25 09:00
MHDA- 2006/05/25 09:00
CRDT- 2006/04/25 09:00
PHST- 2006/04/25 09:00 [pubmed]
PHST- 2006/05/25 09:00 [medline]
PHST- 2006/04/25 09:00 [entrez]
AID - 794 [pii]
AID - 10.1007/s12094-006-0093-x [doi]
PST - ppublish
SO  - Clin Transl Oncol. 2006 Jan;8(1):39-44. doi: 10.1007/s12094-006-0093-x.